Navigation Links
iCo Therapeutics Announces Second Quarter 2014 Financial Results
Date:8/29/2014

VANCOUVER, Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

Second Quarter 2014 Highlights

  • Announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study evaluating the efficacy and safety of iCo-007 after repeated injections in patients with DME. 
  • Poster presentation by research collaborators at the Association of Research and Ophthalmology (ARVO) 2014 Annual Meeting titled "Demographics and Baseline Characteristics of the iDEAL Study: A Randomized, Multi-center, Phase II Study of the safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center".

Subsequent Events to Quarter End

  • Announced that all nominees listed in the management information circular dated May 28, 2014 were elected as directors of the Company at the 2014 Annual Meeting of Shareholders, held on Friday, June 27, 2014.
  • Reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.  The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy.

Summary Second Quarter 2014 Results
iCo incurred total comprehe
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... Netherlands (PRWEB) September 20, 2014 ... technologies to perform a groundbreaking surgery at the specialized ... the mare's superficial digital flexor tendon was ruptured 90% ... kind of injury is a death sentence for a ... America stem cell treatments . This revolutionary ...
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... Cereal grain scientists, quality regulators, ... October 5–8, 2014, for the AACC International (AACCI) ... in Providence, Rhode Island. The comprehensive scientific program ... scientists, chemists, microbiologists, nutritionists, and those interested in ... To date, 1,000 attendees have registered for the ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... Elekta Neuromag(R),the world-leading equipment for non-invasive ... has been ordered by The,Nebraska Medical Center ... ), With a reputation for excellence, ... Center has earned J.D. Power and Associates,Hospital ...
... response to the,recent comments by certain plaintiff law firms ... (the "Company") (OTC,Bulletin Board: CCYG) asserts that the pending ... so in a court of law. To that end, ... LLP as its counsel and,will defend itself vigorously in ...
... Inc. (Nasdaq: CALP ) today announced that ... Mid Cap Growth Conference in Naples, Florida,will be ... EST. Kevin,Hrusovsky, President and CEO of Caliper, will ... live webcast can be accessed at, http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73. ...
Cached Biology Technology:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 2CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... 2014 Nxt-ID, Inc. (Nasdaq: NXTD and ... the growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ... and light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... star Katey Sagal have been cast in Bleed ...
(Date:9/18/2014)... State University researchers have developed a unique method to ... cleanup in rural areas. , The first microbe-powered, ... and quick way to clean up waste from large ... pollution. , Professor Haluk Beyenal and graduate student ... Architecture discuss the system in the online edition of ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
... laboratory mice that bear aggressive human breast cancers, UC ... growth of tumors -- without damage to surrounding healthy ... issue of the Journal of Nuclear Medicine. , "We ... mice. The next step will be clinical testing in ...
... of hearing have found an underlying molecular cause for ... deafness and the organization of liquid crystals, which are ... the inner ear, sound waves cause the basilar membrane ... trigger nerve impulses that are transmitted to the brain. ...
... in collaboration with colleagues from UC Berkeley and StrataGent ... novel pulsed microjet system engineered to deliver protein drugs ... deeper penetration injection systems cause. The research was published ... of Sciences. , The effort to create needle-free ...
Cached Biology News:UC Davis researchers use heated nanoprobes to destroy breast cancer cells in mice 2Scientists identify molecular cause for one form of deafness 2Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2
Porcine Coronary Artery Endothelial Cells (PCAEC) (>500,000 cells)...
Proliferin (N-14)...
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
... Ligase catalyzes the formation of phosphodiester bonds ... DNAs with 3' hydroxyl and 5' phosphate ... optimizes ligation which can be performed in ... not substrates for this enzyme. A ...
Biology Products: